Page 61 - Clinical Development News Today

J&J announces that its Janssen pharmaceutical companies have applied to the European Medicines Agency for an extension of the indication for Rybrevant in combination with chemotherapy for the...

It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).

DUBLIN, Nov. 23, 2023 /PRNewswire/ -- The "Crovalimab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights

Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.

Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The "FLUZONE QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive insights into Fluzone Quadrivalent, a vaccine used for seasonal influenza, across the six major markets. It provides a detailed overview of Fluzone Quadrivalent for seasonal influenza in the 6MM (United States, EU4: Germany, France, Italy, and Spain, and the United Kingdom) during t...

Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The

Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This "Danicopan...

An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).